MedTrace Logo

Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00504933 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 683

Last updated 2012-04-05

No results posted yet for this study

Summary

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

bilastine

20 mg (encapsulated) tablets QD/14days

DRUG

Cetirizine

10 mg (encapsulated) tablets. QD/14 days

DRUG

Placebo

(encapsulated) Tablets QD/14 days

Sponsors & Collaborators

  • Faes Farma, S.A.

    lead INDUSTRY

Principal Investigators

  • Piotr Kuna, Prof. Dr · Barlicki University Hospital, Medical University of Lodz (Poland)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2005-11-30
Completion
2005-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504933 on ClinicalTrials.gov